Despite this, just 12 h treatment with CDF resulted in prolonged inhibition of lymphangiogenesis via continued inhibition of the Vegfc/Flt4/Erk pathway compared with the FDA approved standard of care molecule in renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumour, SM. Here, FLT4 is linked to hereditary clear cell renal cell carcinoma.